ArticleCurrent cancer drug targets2024

CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.

Kelly C Arias Cardenas et al.PubMed ↗Publisher ↗

No numbers read from the abstract.